Lercanidipine

This page contains recent news articles, when available, and an overview of Lercanidipine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Lercanidipine (when available)

Pharmacology and use:
Lercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. For the treatment of Hypertension and management of angina pectoris and Raynaud's syndrome

Mechanism Of Action:
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

News Articles on Lercanidipine

RECORDATI : POSITIVE FIRST NINE MONTHS 2009 RESULTS, SALES AND INCOME INCREASE  -  ‎Oct 30, 2009‎
Agreement with Pharmathen for a new low dose formulation of lercanidipine. - Agreement with Amdipharm for the marketing and sales of TransAct® LAT in Italy ... PR-CANADA.net (press release)

Recordati : Positive First Nine Months 2009 Results, Sales and Income Increase  -  ‎Oct 27, 2009‎
Agreement with Pharmathen for a new low dose formulation of lercanidipine. - Agreement with Amdipharm for the marketing and sales of TransAct(R) LAT in ... American Chronicle

Recordati buys back UK selling rights of its lercanidipine drug for...  -  Jun 17, 2005
MILAN (AFX) - Recordati SpA said it has agreed to repurchase from Napp Pharmaceuticals Ltd selling rights of its anti-hypertensive lercanidipine drug ... Forbes

Recordati receives clearance for anti-hypertensive drug Zanitek in …  -  Jul 27, 2006
Sales of lercanidipine already account for 30 pct of Recordati's pharmaceutical revenues and rose in the first half by more than 25 pct. Forbes

Recordati in sales agreement with Sigma Tau for sale of anti- …  -  Dec 21, 2006
Sales of lercanidipine already account for 30 pct of Recordati's pharmaceutical revenues and rose 26.5 pct in the first nine months of the year. Forbes

Recordati sees 14 pct rise in 2008 net profit  -  Feb 7, 2008
Recordati, whose drug lercanidipine is a calcium channel blocker, said it expected a 10 percent rise in both revenue and earnings before interest and tax. ... Reuters

Recordati signs deal with Meda to sell hypertensive drug in Spain  -  Jul 31, 2007
...has marketing rights for the drug in Germany and Scandinavia. The drug combines lercanidipine and enalapril, two treatments used for high blood pressure. Forbes

Lercanidipine, enalapril and their combination in the treatment of...  -  Feb 26, 2007
The study was presented in abstract form at the XVI European Meeting on Hypertension (J Hyperten 2006; 24(Suppl 4): S420). Correspondence: Dr C Ghezzi, ... Nature.com

Diabetic Nephropathy; Lercanidipine and ramipril reduce albumin …  -  Mar 14, 2005
2005 MAR 14 - (NewsRx.com) -- Lercanidipine and ramipril reduce albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones

RECORDATI: 2007 ACCOUNTS APPROVED BY THE BOARD. …  -  Mar 5, 2008
Sales of lercanidipine, Recordati's original antihypertensive drug, are up by 8.9%. Pharmaceutical chemical sales are EUR 34.0 million, down by 11.3% as ... marketwire.com

Disease Associations; Enalapril plus lercanidipine had better blood …  -  Mar 7, 2006
2006 MAR 7 - (NewsRx.com) -- Enalapril plus lercanidipine had a slightly better blood pressure response rate than enalapril plus hydrochlorothiazide. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Diabetic Nephropathy; Lercanidipine and ramipril reduce albumin …  -  Mar 18, 2005
2005 MAR 18 - (NewsRx.com) -- Lercanidipine and ramipril reduce albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones

Zanidip (Lercanidipine), an In-house Developed Calcium Channel …  -  Jan 17, 2007
This pharmaceutical company intelligence report provides a full review of the company's activities together with five-year sales forecasts for its key ... Free with registration - M2 Presswire - AccessMyLibrary.com

CANCELS AND REPLACES - RECORDATI: ZAN-EXTRA ® APPROVED …  -  Feb 20, 2008
..."Lercanidipine, with a share of 23%, is already a successful product in this market, which for our product represents the fourth largest worldwide and first ... marketwire.com

… Cease Development of Lercanidipine Hydrochloride, Hypertension...  -  Aug 2, 2005
Tokyo, Japan, Aug 2, 2005 - (JCNN) - Tsumura and Dainippon Pharmaceutical have decided to return their right to develop and sell lercanidipine hydrochloride ... Free with registration - JCNN News Summaries - AccessMyLibrary.com

Euronext - Van genoteerde ondernemingen > Persberichten  -  Oct 29, 2008
Launches in all these countries, in which lercanidipine has already obtained the physicians' appreciation, will initiate gradually as from the beginning of ... euronext.com

Press Release: Zanidip (Lercanidipine), an In-house Developed Calcium...  -  Jan 17, 2007
Zanidip (Lercanidipine), an In-house Developed Calcium Channel Blocker, is the Top Selling Product for Recordati. from M2 Presswire. Pay-Per-View - M2 Presswire - HighBeam Research

RECORDATI buys Jaba's pharmaceutical business in Portugal  -  Jul 28, 2006
..."We intend to strengthen the product portfolio of our new subsidiary first of all by launching lercanidipine, our leading product, and over the medium term ... Genetic Engineering News - Genetic Engineering News (press release)

lercanidipine Recordati, Eurand licensing agreement.(Brief Article)  -  Mar 14, 2005
...lercanidipine, lercanidipine hydrochloride, masnidipine, REC 152375, R 75, TJN 324, ZANIDIP, LERDIP, ZANEDIP, LERCADIP, CARDIOVASC, LERZAM, LERGADIP, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones

Diabetic Nephropathy; Reports advance knowledge in diabetic …  -  Apr 18, 2005
Study 1: Lercanidipine and ramipril reduce albumin excretion rate in hypertensive ... We evaluated the effectiveness of lercanidipine, in comparison with ... Pay-Per-View - Diabetes Week - Factiva, from Dow Jones

RECORDATI ACQUIRES A DIRECT PRESENCE IN RUSSIA AND …  -  Mar 7, 2008
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... marketwire.com

… ; NDA submitted to German agency for combination of lercanidipine...  -  Jan 10, 2005
2005 JAN 10 - (NewsRx.com & NewsRx.net) -- Recordati announced that it has submitted a new drug application for a fixed combination of lercanidipine and ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones

… of domestic licensing deal for lercanidipine.(marketing agreement)(...  -  Aug 8, 2005
Tsumara and Dainippon Pharma opt out of domestic licensing deal for lercanidipine.(marketing agreement)(Brief Article). Pharma Marketletter August 8 , 2005 ... $4.95 - Pharma Marketletter - ECNext

… ; NDA submitted to German agency for combination of lercanidipine...  -  Jan 15, 2005
2005 JAN 15 - (NewsRx.com & NewsRx.net) -- Recordati announced that it has submitted a new drug application for a fixed combination of lercanidipine and ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones

레니딥 정'(lercanidipine HCl 10mg)  -  May 15, 2006
...�?�화약품�?� 최근 본태성 고혈압�? 우수한 효과를 나타내는 고혈압치료제 '레니딥 정'(lercanidipine HCl 10mg)�?� 새롭게 발매했다. '레니딥'�?� 다른 칼슘채�?차단제와 ... 메디�?�뉴스

Recordati SpA: 2006 ACCOUNTS APPROVED BY THE BOARD. …  -  Mar 6, 2007
Lercanidipine, Recordati's original antihypertensive drug, continues to perform very well with global sales growing by 21.2%. Pharmaceutical chemicals sales ... Genetic Engineering News - Genetic Engineering News (press release)

Diabetic Nephropathy; Reports advance knowledge in diabetic …  -  Apr 22, 2005
Study 1: Lercanidipine and ramipril reduce albumin excretion rate in hypertensive ... We evaluated the effectiveness of lercanidipine, in comparison with ... Pay-Per-View - Drug Week - Factiva, from Dow Jones

OUTLOOK Recordati Q1 EBIT flat to higher, supported by Orphan Europe ...  -  May 5, 2008
PK - news - people ) in a note said it sees first quarter sales of Recordati's lercanidipine hypertension drug rising 11 percent to 52 million euro. ... Forbes

Recordati Reports Revenue and Earnings Growth in the First Half 2008  -  Jul 30, 2008
Launches in all these countries, in which lercanidipine has already obtained the physicians' appreciation, will initiate gradually as from the second half ... marketwire.com

United BioSource Corp acquires Muse & Associates - Deal Snapshot - …  -  Jun 28, 2006
Zanidip (lercanidipine hydrochloride) Hypertension M Muse Erectile Dysfunction M Metformin Meda…and late phase allergic responses associated with allergies ... Pay-Per-View - deals - Alacra Store

Atherosclerosis; Recent studies add new data to atherosclerosis...  -  Mar 15, 2005
In addition, lercanidipine inhibited the release of metalloproteinases in the ... "Experiments performed with lercanidipine enantiomers or other ... Pay-Per-View - Science Letter - Factiva, from Dow Jones

Effects of Dual Blockade of Renin–Angiotensin System on Concentric...  -  Aug 2, 2007
Twenty-four never-treated hypertensive patients with LV concentric hypertrophy were randomized to ramipril + candesartan or ramipril + lercanidipine. ... Nature.com

Atherosclerosis; Recent studies add new data to atherosclerosis...  -  Mar 19, 2005
In addition, lercanidipine inhibited the release of metalloproteinases in the ... "Experiments performed with lercanidipine enantiomers or other ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones

Recordati SpA: Positive First Nine Months 2007 Results, Sales and …  -  Oct 25, 2007
Zanipress®, our new antihypertensive product which associates lercanidipine and enalapril in a fixed combination, was launched in Germany in April by our ... marketwire.com

Atherosclerosis; Findings describe new data in atherosclerosis...  -  Mar 28, 2005
In addition, lercanidipine inhibited the release of metalloproteinases in the ... "Experiments performed with lercanidipine enantiomers or other ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones

Bourse en ligne, actualité des cours de la bourse en ligne avec LCI  -  Feb 20, 2008
Lercanidipine est déjà un succès sur ce marché (23 %), 4ème au monde et 1er hors d'Europe, et peut voir sa position s'améliorer grâce à cette nouvelle ... TF1

Atherosclerosis; Findings describe new data in atherosclerosis...  -  Apr 1, 2005
In addition, lercanidipine inhibited the release of metalloproteinases in the ... "Experiments performed with lercanidipine enantiomers or other ... Pay-Per-View - Drug Week - Factiva, from Dow Jones

University of Washington; Findings describe new data in atherosclerosi...  -  Mar 30, 2005
In addition, lercanidipine inhibited the release of metalloproteinases in the ... "Experiments performed with lercanidipine enantiomers or other ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones

Press Release: euNetworks Launches New Release Of Online Customer …  -  May 20, 2008
Current Growth Drivers Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati's top selling product by a considerable margin, ... Pay-Per-View - M2 Presswire - HighBeam Research

Recordati FY net, EBIT rise on favourable product mix; ups div payout...  -  Feb 8, 2007
Lercanidipine sales in 2006 rose 21.2 pct and in 2007 are seen up 10-15 pct. Recordati also said its research and development costs rose 1.0 pct in 2006 and ... Forbes

Recordati signs an agreement with Osmotica Pharmaceutical Europe for ...  -  Dec 23, 2005
Under this agreement Osmotica will apply its Osmodex™ technology to the development of a formulation of lercanidipine with new and improved release ... biotech-intelligence.com

Article: Fix your kicks, save your soles. - Chicago Tribune (Chicago,...  -  Apr 27, 2006
Lercanidipine Acts in a Unique Way to Lower Blood Pressure While Offering Fewer Side Effects Forest Laboratories, Inc. announced that findings from a ... Pay-Per-View - Chicago Tribune - HighBeam Research

J Herb Co Ltd acquires Tsumura & Co-Health Food Bus from Tsumura & …  -  Mar 3, 2006
Drug Application (NDA) with the Food and Drug Administration for lercanidipine… RECORDATI SPA-COMPANY REPORT · RECORDATI SPA-COMPANY REPORT ... Pay-Per-View - deals - Alacra Store

Recordati SpA: POSITIVE FIRST QUARTER 2007 RESULTS. REVENUE …  -  May 3, 2007
In January Recordati Ireland Ltd. initiated commercial operations in the Irish pharmaceutical market where Zanidip(R) (lercanidipine) is now promoted ... Genetic Engineering News - Genetic Engineering News (press release)

RECORDATI : RESULTATS PRELIMINAIRES 2008 EN LIGNE AVEC LES …  -  Jun 4, 2006
The mutual recognition procedure for the approval of our new fixed combination of lercanidipine and enalapril throughout the European Union was completed; ... Bolsamania.fr

Site d'analyses et de conseils quotidiens sur les valeurs de la...  -  Jul 2, 2008
...the growth of our original antihypertensive drug lercanidipine and the careful ... the most recent of which, lercanidipine, a latest generation calcium ... NeoBourse - NeoBourse (Abonnement)

Research & Markets: New Report Examines the Historical and …  -  Dec 28, 2006
Lercanidipine + enalapril Optruma Testopatch Growth resistors Navelbine ... Lercanidipine + enalapril Fractal 113 Diafusor Lercan Urology Permixon ... Free with registration - Business Wire - AccessMyLibrary.com

Euronext - Van genoteerde ondernemingen > Persberichten  -  Dec 18, 2008
In 2010, due to the expiry of the lercanidipine patent in the main European countries, a reduction in sales of the product is expected. ... euronext.com

Research and Markets: Recordati Is Active In the Following Areas of …  -  Dec 21, 2006
Zanidip (lercanidipine), an in-house developed calcium channel blocker, ... Zanitek (lercanidipine+enalapril) is a new fixed combination treatment for ... $4.95 - Business Wire - ECNext

Research & Markets: New Report Examines the Historical and Forecast …  -  Dec 28, 2006
Lercanidipine + enalapril Optruma Testopatch Growth resistors Navelbine ... Lercanidipine + enalapril Fractal 113 Diafusor Lercan Urology Permixon ... $4.95 - Business Wire - ECNext

Recordati Is Active In the Following Areas of Research: Cardiovascular...  -  Dec 20, 2006
Current Growth Drivers Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati's top selling product by a considerable margin, ... $4.95 - M2 Presswire - ECNext

Recordati Q1 net profit up 10.4 pct; just beats forecasts UPDATE  -  May 3, 2007
Sales of Lercanidipine, a calcium channel blocker used to treat hypertension, grew 7.3 pct to 46.9 mln eur. The sharpest rise was in France, ... Forbes

Recordati опубликовала бизне�?-план на 2009–2011 гг.  -  Dec 19, 2008
В начале 2009 г. компани�? намерена выпу�?тить на о�?новные европей�?кие фармрынки новый продукт – комбинированный препарат lercanidipine + enalapril дл�? ... Фармацевтиче�?кий ве�?тник

Factiva Search  -  Mar 15, 2005
Diabetic Nephropathy; Lercanidipine and ramipril reduce albumin excretion in type 2 diabetes. 15 March, 2005 Life Science Weekly ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Factiva Search  -  Mar 14, 2005
Diabetic Nephropathy; Lercanidipine and ramipril reduce albumin excretion in type 2 diabetes. 14 March, 2005 Obesity & Diabetes Week ... Pay-Per-View - Obesity & Diabetes Week - Factiva, from Dow Jones

LifeCycle Pharma Successfully Completes EUR 15 Million Financing.  -  May 17, 2005
LifeCycle Pharma is collaborating with Recordati SpA on a modified-release tablet formulation of Lercanidipine. Lercanidipine is an oral calcium-channel ... $4.95 - Business Wire - ECNext

Press Release: Nebivolol Lowers Blood Pressure in Mild-to-Moderate …  -  Sep 4, 2007
Article: Forest Laboratories Updates Lercanidipine ... PR Newswire; November 2, ... Lercanidipine is licensed to Forest Laboratories, Inc. from the . ... Pay-Per-View - PR Newswire - HighBeam Research

Press Release: Data Presented at ASH Demonstrate Nebivolol Lowers …  -  May 21, 2007
Article: Forest Laboratories Updates Lercanidipine ... PR Newswire; November 2, ... Lercanidipine is licensed to Forest Laboratories, Inc. from the . ... Pay-Per-View - PR Newswire - HighBeam Research

Italy Stocks Update: Gemina, Fiat, Luxottica, Seat, Tiscali  -  Sep 22, 2008
...positive and we expect additional transactions to be announced that help reduce the company's reliance on lercanidipine,'' Goldman Sachs analysts wrote. ... Bloomberg

Press Release: "Recordati: Prospects to 2010" by Espicom Healthcare …  -  Dec 18, 2006
Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati s top selling product by a considerable margin, accounting for around ... Pay-Per-View - M2 Presswire - HighBeam Research

Big Pharma erodes Govt's pricing plans  -  Nov 3, 2007
...and the blood-pressure-lowering medication lercanidipine -- they will still result in a $104 million reduction in the savings that were due to flow from ... The Australian

Force of blood  -  Nov 12, 2006
Included in this group are drugs such as amlodipine, diltiazem HCl, felodipine, isradipine, lercanidipine HCl, lacidipine, nifedipine, nicardipine HCL, ... Malaysia Star

[쿠키뉴스] 갓 구워낸 바삭바삭한 뉴스  -  Jul 2, 2008
...�? ACE억제제와 안지오�?신II수용체 길항제 �?는 병용(�?날�?�프릴+lercanidipine 등) �?� 맥압�?는 특히 우수한 �?향�?� 준다는 �?��?�터�?� 얻어지고 있다. ... 쿠키뉴스

[한국형 �?�러스터가 �?��?�?�다] <2> 한국형 모�?� 창조하�?  -  Sep 19, 2006
...선정�?� 8000만�?�?� 개발�?금 지�?과 �?산기술연구�?과 함께 고혈압치료제 �?료�?� 레르카니디핀(Lercanidipine)�?� 개발, 올해만 10억�?�?� �?매하는 성과를 거뒀다. ... 서울경제

::: 경�?��?�보 - 수�?�권 1등신문 :::  -  Sep 16, 2005
...추진단�? 따르면 4개�?� 과제는 △고혈압 치료제 Lercanidipine�?� 효과�?�?� 합성법 개발((주)대�?�화학) △과민성 방광치료제�?� 톨테로딘�?� 경제�?�?� 제조공정 개발((주) ... 경�?��?�보

[2006 중소기업경�?대�?] 대�?�화학  -  Nov 13, 2006
...지난해 하반기�?는 고혈압 치료물질 개발과제 사업�?로 선정�?� 8000만�?�?� 개발�?금 �?� 지�?받아 �?산기술연구�?과 고혈압치료제 �?료�?� 레르카니디핀(Lercanidipine)�?� ... 서울경제

Recordati SpA : FINALIZES ITS ACQUISITION OF YENI ILAÇ IN TURKEY  -  Dec 23, 2008
...the most recent of which,lercanidipine, a latest generation calcium channel blocker for thetreatment of hypertension, is the company's leading product. ... International Business Times

RECORDATI SUCCESSFULLY COMPLETES THE SILODOSIN DOUBLE- …  -  Sep 26, 2007
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... Genetic Engineering News - Genetic Engineering News (press release)

Recordati Licenses Kentera(R) From Watson Pharmaceuticals Inc. (USA) ...  -  Jan 16, 2008
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... Genetic Engineering News - Genetic Engineering News (press release)

Recordati: Orphan Europe Filed Carbaglu NDA With the FDA in the US  -  Apr 21, 2008
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... Genetic Engineering News - Genetic Engineering News (press release)

Recordati sees gross margin improvement slowing after Q3's 1 pct...  -  Oct 26, 2007
Zanipress, a combination of Recordati's top-selling lercanidipine hypertension drug with enalapril, is already on sale in Germany and generating sales at a ... ABCmoney.co.uk

Recordati SpA : OBTAINS EUROPEAN LICENSE FOR PITAVASTATIN  -  Oct 24, 2008
...the most recent of which,lercanidipine, a latest generation calcium channel blocker for thetreatment of hypertension, is the company's leading product. ... International Business Times

… transfers back to Recordati the rights for the sale of Corifeo...  -  Apr 24, 2006
Brussels (Belgium), 24 April 2006 - UCB announces that it has reached an agreement with Recordati to transfer back the sales and marketing rights in Germany ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com

Research and Markets: Recordati Company Intelligence Reports Provide ...  -  Aug 3, 2007
THERAPEUTIC AREA FOCUS Key product analysis and forecasting Cardiovascular Zanidip/Zanedip (lercanidipine) Central Nervous System Elopram/Entact ... Free with registration - Business Wire - AccessMyLibrary.com

Recordati's like 2004 pharma sales grow 8.4%.  -  Mar 14, 2005
Growth in pharmaceuticals was attributed to the success of Recordati's cardiovascular drug Zanidip (lercanidipine), turnover of which increased 25.4% to ... Free with registration - Pharma Marketletter - AccessMyLibrary.com

Forest Labs.(Phase II)  -  Jan 1, 2005
Forest Labs (New York, MY) did not meet all of its endpoints for its Phase II study of lercanidipine, a hypertension treatment. Free with registration - Applied Clinical Trials - AccessMyLibrary.com

ATC/DDD classification (temporary).(ATC/DDD Classification)(anatomical...  -  Jan 1, 2007
...and calcium Enalapril and C09BB02 channel blockers lercanidipine Immunosuppressive agents Immunosuppressants Immunosuppressive agents Immunosuppressants ... Free with registration - WHO Drug Information - AccessMyLibrary.com

Recordati to Meet With the Financial Community and Specialized Press...  -  Feb 2, 2007
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... Genetic Engineering News - Genetic Engineering News (press release)

Drug treatments: Calcium channel blockers  -  Apr 6, 2007
Newer drugs, such as lercanidipine, may reduce or avoid many of these side effects. Grapefruit and Seville oranges (used in some marmalades) may have a ... Waco Tribune-Herald - Waco Tribune Herald

Recordati acquires Turkish drug producer  -  Oct 30, 2008
...time through licensing agreements with local companies that have allowed it to bring its original products to this market, particularly lercanidipine. ... Today's Zaman

Recordati's pharmachem unit back in the black  -  Mar 10, 2005
Growth in pharmaceuticals was attributed to the success of Recordati's cardiovascular drug Zanidip (lercanidipine), turnover of which increased 25 per cent ... In-PharmaTechnologist.com

Italian pharmaceutical group, Recordati, opens EUR 28 M plant in …  -  Oct 14, 2005
The plant is currently dedicated to the manufacturing of proprietary pharmaceutical active ingredients, particularly lercanidipine (Zanidip). ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com

Italian pharmaceutical firm Recordati (Milan, Italy) reports that the...  -  Sep 1, 2006
Federal Institute for Drugs and Medical Devices (BfArM) has approved its new fixed-combination antihypertensive drug Zanitek (lercanidipine/enalapril). Free with registration - Applied Clinical Trials - AccessMyLibrary.com

Excellence in Research & Development  -  Jun 30, 2007
Another candidate under development is the polymorphic form of active API, polymorphic form of lercanidipine and the process for the preparation thereof. ... Express Pharma

… back to Recordati the rights for the sale of Corifeo(R) (Lercanidip...  -  Apr 26, 2006
26 Apr 2006 - UCB announced that it has reached an agreement with Recordati to transfer back the sales and marketing rights in Germany of Corifeo®, ... chemie.de

LifeCycle Pharma A/S Announces Successful Completion of Pilot Studies...  -  May 28, 2008
...service agreement which encompasses the development of a novel version of Recordati's lercanidipine (Zanidip®) for the treatment of hypertension. ... Genetic Engineering News - Genetic Engineering News (press release)

Recordati sells its pharmaceutical chemicals plant in Spain  -  Jan 17, 2006
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... biotech-intelligence.com

Recordati appoints Gianni Soro General Manager of Pharmaceuticals …  -  Dec 13, 2006
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... Genetic Engineering News - Genetic Engineering News (press release)

Effect of valsartan addition to amlodipine on ankle oedema and …  -  Jul 28, 2006
Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in ... Nature.com

Labopharm Enters Into UK Distribution Agreement with Recordati for …  -  Nov 16, 2005
...the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product ... $4.95 - PR Newswire - ECNext

Recordati's first-half net income jumps 16.7%.  -  Aug 18, 2008
...process approval throughout the European Union, Norway and Iceland for its new fixed-dose combination antihypertensive of lercanidipine and enalapril. ... $9.94 - Pharma Marketletter - Alacra Store

RESEARCH & DEVELOPMENT NEWS IN BRIEF  -  Mar 21, 2005
The antihypertensive agent TJN-324 (lercanidipine) under codevelopment with Dainippon Pharmaceutical has completed PIII in Japan but this agent is not ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones

Italy/Turkey generics: Turkish delight  -  Oct 30, 2008
The timing of the deal is also propitious for its lead cardiovascular candidate, the fixed-dose combination of Zanitech (lercanidipine plus enalapril), ... $34.00 - EIU Country Analysis - Alacra Store

Recordati confirms 2008 targets, presents 2009-2011 estimates.  -  Dec 18, 2008
For 2010, however, Recordati projects a certain slowdown as its Lercanidipine licence for Europe will expire. The revenue is seen at EUR 700 million-720 ... $9.94 - M2 Europharma - Alacra Store

Merger and Acquisition Scenario  -  Mar 11, 2006
Celexa, Namenda, Benicar, Campral, Combunox, RGH-188, GRC 3886, Desmoteplase, CCR1 Antagonists, Milnacipran, Tiazac and Lercanidipine. ... $250.00 - Revere Reports - Revere

Merger and Acquisition Scenario  -  Apr 15, 2006
Celexa, Namenda, Benicar, Campral, Combunox, RGH-188, GRC 3886, Desmoteplase, CCR1 Antagonists, Milnacipran, Tiazac and Lercanidipine. ... $250.00 - Revere Reports - Revere

Merger and Acquisition Scenario  -  May 13, 2006
Celexa, Namenda, Benicar, Campral, Combunox, RGH-188, GRC 3886, Desmoteplase, CCR1 Antagonists, Milnacipran, Tiazac and Lercanidipine. ... $250.00 - Revere Reports - Revere

Daiichi Sankyo.(Update) | Article from Medical Marketing & Media | …  -  Dec 1, 2008
Daiichi Sankyo Hypertension (Ph. III) Lercanidipine ... Ill-fast track) Prasugrel Daiichi Sankyo/Eli Lilly Acute Coronary Syndrome ... ... Pay-Per-View - Medical Marketing & Media - HighBeam Research

Factiva Search  -  Jan 12, 2005
Recordati; NDA submitted to German agency for combination of lercanidipine and enalapril. 12 January, 2005 Biotech Week ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones

Factiva Search  -  Jan 10, 2005
Hypertension; NDA submitted to German agency for combination of lercanidipine and enalapril. 10 January, 2005 Health & Medicine Week ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones

Press Release: Recordati Is Active In the Following Areas of Research:...  -  Dec 20, 2006
Article: Zanidip (Lercanidipine), an In-house Developed Calcium Channel ... M2 Presswire; January 17, 2007 ; 700+ words ... ... corporate events. ... Pay-Per-View - M2 Presswire - HighBeam Research

Scriptlines: Zanidip.(Brief article)  -  Apr 1, 2006
Recordati has added a 20mg strength to its Zanidip range (lercanidipine hydrochloride). Pack Size: 28 tablets Pip code: 290-5768 Recordati Pharmaceuticals ... $4.95 - Chemist & Druggist - ECNext

Brand Names/Synonyms:
Lercanidipine is also known by the following brand names and/or synonymsLercanidipine; Lercanidipine [Inn]

Drug Category:
Lercanidipine is categorized under the following by the FDA: Antihypertensive Agents; ATC:C08CA13

Dosage Forms:
Not Available

Absorption:
Not Available

Interactions:
Not Available

Chemical IUPAC Name:
methyl[2-(3,3-diphenylpropyl-methyl-amino)-1,1-dimethyl-ethyl]2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.